Xenetic Biosciences is trading at $1.80, down 10.45%, amid a sharp market sell-off and biotech weakness; no company-specific catalyst has been confirmed.

  • The XBI ETF is down 5.19%, reflecting biotech sector weakness.
  • The company’s November 4 announcement of an oral presentation at the ASH meeting is prior news and is not a clear explanation for today’s decline.